Eli Lilly, the maker of Ozempic, has developed a weight loss pill that could work as well. The new weight loss pill, ...

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a ...

In the December quarter, the company's management said it plans to double the firm's pen capacity over the next couple of ...

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed ...

The latest discovery in obesity medicine will be available in less invasive creams and patches, known as transdermal drug ...

The National Institutes of Health will provide private health data to researchers for U.S. health chief Robert F. Kennedy Jr.

With President Trump's on-off tariffs causing huge uncertainty in recent weeks, some value stocks have been getting even ...

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 ...

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.